<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661254</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200733</org_study_id>
    <secondary_id>2020-A01871-38</secondary_id>
    <nct_id>NCT04661254</nct_id>
  </id_info>
  <brief_title>Treg Cell Therapy in Liver and Kidney Transplantation - Preclinical Validation of Batches of Treg Cells Amplified in Vitro</brief_title>
  <acronym>PRE-TREG</acronym>
  <official_title>Treg Cell Therapy in Liver and Kidney Transplantation - Preclinical Validation of Batches of Treg Cells Amplified in Vitro</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kidney and liver transplantation requires a fine tuning of immune responses in order to&#xD;
      achieve long term operational tolerance with immunosuppressants or immune modulators.&#xD;
      Numerous experimental findings indicate that CD4+ FOXP3 expressing regulatory T (Treg) cells&#xD;
      play a central role in the induction of tolerance to the grafts indicating that the use of&#xD;
      Treg cells may be an innovative therapeutic strategy in kidney transplantation that would&#xD;
      enable the diminution of immunosuppressive drugs or even their discontinuation, thus&#xD;
      decreasing their risk of adverse events.&#xD;
&#xD;
      As human Treg cells represent less than 10% of CD4+ T cells, and because it has been shown in&#xD;
      mice that a dose of 2*104 polyclonal Tregs/g was necessary to induce tolerance in animal&#xD;
      models of solid organ transplantation, it is mandatory to expand human Treg cells ex vivo,&#xD;
      after isolating them from peripheral blood. The investigators previously defined a protocol&#xD;
      for Treg cell isolation and expansion in clinical grade conditions (cGMP) that enabled us to&#xD;
      obtain the expected number of expanded cells maintaining high levels of FOXP3 (3).&#xD;
&#xD;
      The investigators therefore hypothesize in humans, as it has been already shown in mice, that&#xD;
      the infusion of autologous expanded polyclonal Treg cells would lead to the obtaining of&#xD;
      operational tolerance in kidney and liver graft in association with classical&#xD;
      immunosuppressants and an expectable diminution of those.&#xD;
&#xD;
      To this end, it is necessary to have pre-clinical batches of expanded Treg cells validated by&#xD;
      the National Agency for Medicines and Health Products Safety validate (ANSM). The&#xD;
      investigators therefore plan to have 4 batches from 2 liver transplant patients and 2 kidney&#xD;
      transplant patients validated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validate 4 preclinical batches of Treg cells from 2 liver transplant patients and 2 kidney transplant patients</measure>
    <time_frame>At day 10</time_frame>
    <description>Treg cells produced according to the expansion protocol defined by verifying the compliance of the batches according to the requirements of the guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Product) by respecting the validation and batch release criteria defined in this protocol.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Lymphapheresis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood is drawn from one of the patient's two arms and passes through a separation circuit. After removing the white blood cells, it is reinjected into the other arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lymphapheresis</intervention_name>
    <description>- From the blood product of lymphapheresis: Autologous naïve regulatory CD45RA+CD4+CD25+FoxP3+ T lymphocytes (Tregs) selected and amplified ex vivo; obtained by selection and sorting of CD4+CD25 +CD127lowCD45RA+ cells, derived from lymphapheresis and amplified ex vivo for 10 +/- 1 days, under cGMP condition in the presence of IL2 and Rapamycin</description>
    <arm_group_label>Lymphapheresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For liver transplant patients:&#xD;
&#xD;
          -  Liver transplantation carried out for 1 to 3 months for alcoholic cirrhosis;&#xD;
&#xD;
          -  Normal liver biological test;&#xD;
&#xD;
          -  Normal hepatic morphological assessment;&#xD;
&#xD;
        For kidney transplant patients:&#xD;
&#xD;
          -  Renal transplantation carried out for 3 to 6 months for any disease requiring renal&#xD;
             transplantation;&#xD;
&#xD;
          -  Normal renal biological assessment;&#xD;
&#xD;
          -  Normal renal morphological assessment;&#xD;
&#xD;
          -  DSA &lt;1500 MFI at inclusion&#xD;
&#xD;
        Common criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 70 years&#xD;
&#xD;
          -  GB ≥1500 / mm3&#xD;
&#xD;
          -  Hemoglobin level&gt; 10g / 100ml&#xD;
&#xD;
          -  Platelets&gt; 50,000 / μl&#xD;
&#xD;
          -  Weight&gt; 40Kg&#xD;
&#xD;
          -  Informed and signed consent;&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For liver transplant patients:&#xD;
&#xD;
        - Hepatocellular carcinoma or history of another cancer;&#xD;
&#xD;
        For kidney transplant patients:&#xD;
&#xD;
        - Kidney cancer or a history of another cancer&#xD;
&#xD;
        Common criteria:&#xD;
&#xD;
          -  Active infectious diseases: positive serology for hepatitis A, B or C, HIV, HTLV, CMV&#xD;
             and EBV;&#xD;
&#xD;
          -  Associated autoimmune disease, including type 1 diabetes;&#xD;
&#xD;
          -  GB &lt;1500 / mm3;&#xD;
&#xD;
          -  Any contraindication to citrate and calcium gluconate.&#xD;
&#xD;
          -  Pregnancy or lactating woman&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Patient deprived of liberty or under administrative security measure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MIYARA Makoto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP - Pitié Salpêtrière hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MIYARA Makoto, MD, PhD</last_name>
    <phone>+33 1 42 17 84 91</phone>
    <email>makoto.miyara@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pitié Salpêtrière hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>CONTI Filomena, MD, PhD</last_name>
      <phone>+33 1 84 82 74 21</phone>
      <email>filomena.conti@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié Salpêtrière hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>BARROU Benoit, MD, PhD</last_name>
      <phone>+33 1 42 17 71 62</phone>
      <email>benoit.barrrou@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

